World Lung 2025 – crossing curves in lung cancer
Tolerability could decide first-line therapy in EGFRm disease.
World Lung 2025 – Summit's Harmoni guessing game
Investors now have more reasons to doubt Harmoni's ability to back US approval.
Survival questions delay bemarituzumab
Ocular toxicities could be the reason.
Zymeworks becomes the latest mesothelin dropout
The group cans ZW171 after “on-target, off-tumour toxicity”.
Ivonescimab back in tune
China's Harmoni-A trial hits on overall survival, but hopes for a global phase 3 seem optimistic.
World Lung 2025 preview – best of the rest
Posters and mini-orals include another VEGF bispecific.
Pfizer’s Global Blood buy fails to Thrive
Inclacumab fails, and osivelotor is on hold.
